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Transcriptional Corepressors in Cancer
Emerging Targets for Therapeutic Intervention
Petros D. Grivas, MD, PhD1 and Athanasios G. Papavassiliou, MD, PhD2
The normal cell transcriptional process entails a high degree of combinatorial effects and time-dependent ‘‘flexibility’’ to translate cel-
lular signaling into differential gene expression levels. Transcriptional corepressors can function as histone-modifying enzymes to reg-
ulate epigenetic events, modulate chromatin structure, and hence control transcriptional activity. Various corepressor complexes have
been described; qualitative and quantitative alterations of corepressors can crucially influence the transcriptional output of both nor-
mal and malignant cells. Because these molecules can exert epigenetic control of tumorigenic signaling pathways, they can be con-
sidered potential regulators of cancer cell-related phenomena. Alterations of the expression level and/or function of transcriptional
corepressors have been reported in a wide range of human cancers; thus, corepressors may present rational therapeutic targets as
well as potential biomarkers of response to selective therapeutic interventions. Deeper insights into the context-specific and time-
specific physical connections among transcription factors, coregulators, and gene regulatory elements, as well as epigenetic modifi-
cations, and their interactions, can enhance the capacity to interfere with small molecules that may restore the normal transcrip-
tome/interactome in a cancer cell. There are several conceivable mechanisms of corepressor targeting in cancer that create
enthusiasm. However, design, discovery, and testing of such innovative treatment approaches require extensive elaboration before
they can achieve practical implementation in the clinic. Cancer 2013;119:1120-8.VC 2012 American Cancer Society.
KEYWORDS: transcriptional corepressors, breast cancer metastasis suppressor 1, RE1-silencing transcription factor corepressor,
C-terminal–binding proteins, nuclear receptor corepressors 1 and 2, nucleosome remodeling and histone deacetylase, runt-related
transcription factor, drug target, cancer treatment.
INTRODUCTION
Carcinogenesis is a multistep process emanating from the accumulation of genetic and epigenetic alterations in genes that
regulate cell proliferation, growth, differentiation, adhesion, migration, angiogenesis, and apoptosis. Modulation of gene
expression relies on the dynamic balance and spatiotemporal control of specific transcription factors that interact with the
basal transcriptional apparatus as well as with transcriptional coregulators (corepressors and coactivators), resulting in a
multicomplex protein network.1,2 Transcriptional coregulators contribute to the accuracy of this circuitry and can func-
tion as (or cross-talk with) histone-modifying enzymes to control epigenetic events; modify chromatin structure; and,
thus, regulate gene expression patterns.3 Specifically, corepressor protein complexes can mediate enzymatic repression of
gene transcription through multiple biochemical mechanisms.3,4
Diverse corepressor complexes have been identified. These include nuclear receptor corepressor 1 (NCoR1),
NCoR2/silencing mediator for retinoid and thyroid hormone receptors (NCoR2/SMRT), C-terminal–binding proteins
(CTBP1, CTBP2), RE1-silencing transcription factor (REST)/neural-restrictive silencing factor (REST/NRSF), Rest cor-
epressor (RCOR/CoREST), runt-related transcription factor (RUNX), breast cancer metastasis suppressor 1 (BRMS1),
BTG3-associated nuclear protein/scaffold-matrix–associated region 1-binding protein (BANP/SMAR1), zinc-finger and
breast cancer type 1 susceptibility protein (BRCA1)-interacting protein with a Kruppel-associated box (KRAB) zinc finger
domain 1 (ZBRK1/ZNF350), nuclear receptor-interacting protein 1 (NRIP1/RIP140), nucleosome remodeling and his-
tone deacetylase (NURD), and Swi-independent 3 (SIN3).
Mechanistically, it is suggested that transcriptional corepressors bind to nuclear receptors in the absence of their
ligand; whereas the presence of ligand can change the receptor configuration, favoring binding to coactivators, thus stimu-
lating gene transcription.5 The NCoR1-SMRT complex, the SIN3 complex, the corepressor Alien, and orphan nuclear
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receptors are paradigms of this mechanism, acting as con-
stitutive repressors.5 Alternatively, a ‘‘competitive’’
dynamic balance between coactivators and corepressors is
proposed as another putative mechanism of transcription
regulation, with the release of a corepressor and the bind-
ing of a coactivator marking a new transcription cycle. A
unique category of corepressors, namely, receptor-inter-
acting protein 140 (RIP140) and ligand-dependent core-
pressor (LCoR), manifests agonist/antagonist bound-
dependent corepression.5,6 Overall, cells can modulate
corepressor complexes in a multilevel manner to achieve a
high degree of transcriptional fine-tuning. Apart from
ligand-binding–induced, conformational changes result-
ing in the dissociation of corepressors, such modulation
also can be achieved through post-translational modifica-
tions followed by nuclear export and/or degradation of
the corepressor.7 Therefore, qualitative and quantitative
changes of corepressors can play a key role in the tran-
scriptional output of both normal and tumor cells. The
functional role of transcriptional corepressors can vary in
a temporal and spatial manner (‘‘pleiotropic activity’’),
participating in normal cell differentiation and tissue ho-
meostasis as well as in cell transformation and tumor pro-
gression (Table 1).4,8-30 In that these intricate protein
complexes can affect oncogenic signal-transduction cas-
cades, they constitute potential regulators of self-sustained
cell proliferation, resistance to apoptosis, unrestrained
migration, angiogenesis, and metastasis.
A volume of data has documented alterations in the
structure, expression level, and/or function of transcrip-
tional corepressors in a broad array of human malignan-
cies.8,31,32 It becomes evident that corepressors may
function as rational therapeutic targets and/or potential
biomarkers of response to selective chemotherapy regi-
mens. Here, we present selected examples of this relatively
novel and challenging therapeutic concept.
Transcriptional Corepressors: Paradigms of
Potential Tumor Targeting
Nuclear receptor corepressor 1 and nuclear
receptor corepressor 2/silencing mediator for
retinoid and thyroid hormone receptors
NCoR1 and NcoR2 are archetype transcriptional
corepressors, and their structure and role have been well
described.33-36 Tumorigenic roles have been recognized
in acute promyelocytic leukemia (APL), which results in
fusion oncoproteins (promyelocytic leukemia [PML]-reti-
noic acid receptor alpha [RARa] or PML zinc finger
[PLZF]-RARa) that sustain NCoR1 interactions, leading
to a condensed structure of chromatin and, hence, pre-
venting RARa-mediated cell differentiation.37 In contrast
to PML-RARa, PLZF fusion protein is resistant to phar-
macologic doses of retinoic acid; this resistance might be
overcome by the addition of histone deacetylase (HDAC)
inhibitors. In acute myeloid leukemia (AML), the AML1-
821 corepressor (ETO) fusion oncoprotein can recruit
NCoR1, hindering transcription regulation.38 The revela-
tion of a functional role for NCoR1 in leukemia illustrates
the importance of transcriptional corepressors in media-
ting tumorigenic actions and provides a rational for
HDAC targeting. For example, HDAC inhibitors
resulted in myeloid cell differentiation in vitro, corre-
sponding to increased histone 3 and histone 4 acetylation;
however, they did not alter ncor1 or ncor2 gene
expression.39
Expression profiling of solid tumors has revealed
alterations in NCoR1/NCoR2 expression and localiza-
tion.40-43 These alterations may have prognostic value
and/or may predict response to specific therapeutic
interventions, such as response to tamoxifen in estrogen
receptor (ER)-positive breast cancer. In colorectal cancer,
which is not considered hormone-dependent, post-trans-
lational modifications of NCoR1 and NCoR2 can affect
their cytoplasmic localization, hindering b-catenin bind-
ing to lymphoid enhancer factor/T-cell factor (LEF/TCF)
target genes and promoting TCF4 transcriptional repres-
sion.44,45 It is noteworthy that corepressor changes can
occur within the tumor cells and/or in the surrounding
microenvironment, which appears to exert an important
role in tumor initiation and progression. There is consid-
erable uncertainty in the timing and degree of corepressor
alteration with regard to tumor development; however,
thorough understanding of such molecular interplays can
provide a platform for testing novel therapeutic regimens
with or without additional hormone and/or biologic
treatments.
C-terminal–binding proteins 1 and 2
CTBP1 and CTBP2 are 2 similar, highly conserved
corepressors that have been linked to cancer progression
and can be regarded as putative therapeutic targets.10,11
CTBPs may promote cell proliferation, epithelial-mesen-
chymal transition (EMT), and invasiveness, although they
may inhibit apoptosis through suppression of INK4
(cyclin-dependent kinase inhibitor 2A gene) cell-cycle
control proapoptotic genes11; this appears to be relevant
in hepatocellular carcinoma.12 The activities of CTBP1
and CTBP2 are context-dependent and time-dependent.
CTBP1 is associated with ERa trans-repression, whereas
its deregulation can deform normal transcriptional activ-
ity in breast cancer cells.13,46 In colorectal cancer, CTBP
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up-regulation has been recognized as an event downstream
of adenomatous polyposis coli (APC) loss and has been
correlated with alternative reading frame (ARF) loss.47
However, low CTBP levels in melanoma allow up-regula-
tion of LEF/TCF-related genes, contributing to invasion.48
The compound 4 methylthio-2-oxobutyric acid (MTOB)
can bind to CTBP, triggering conformational changes that
result in CTBP dislocation from target-gene promoters.10
Alternatively, reduction of nicotinamide adenine dinucleo-
tide (NADH) levels with antioxidants may distort CTBP
binding to its interacting proteins.8,49
Rest corepressor and runt-related
transcription factor
CoREST forms a complex with REST to repress tar-
get-gene transcription and acts as a docking platform for
the assemblage of HDAC1/HDAC2, BRCA2-associated
factor 35 (BRAF35), BRAF35-HDAC complex protein
(BHC80), and lysine-specific histone demethylase 1
(LSD1).17 LSD1 is up-regulated in a gamut of solid
tumors and has been associated with a poor prognosis.50-
52 However, abnormal epigenetic silencing of tumor sup-
pressor genes by LSD1 has been demonstrated in colo-
rectal cancer cell lines.53 LSD1 inhibition, combined with
DNA methyltransferase inhibition, may re-establish the
expression of repressed genes. CoREST can also form a
larger complex with ZNF217, a candidate oncogene in
breast cancer; this has been correlated with loss of trans-
forming growth factor-beta (TGF-b) responsiveness and
repression of tumor suppressor genes, such as p15ink4b.18
CoREST can also participate in complex formation with
switch/sucrose nonfermentable (SWI/SNF) and CTBP,
resulting in tumorigenic activity.8,54
Transcription factors of the RUNX family were iden-
tified in embryonal carcinoma cells after RAR-induced dif-
ferentiation. The oncogenic capacity of RUNX2 was
unveiled by the creation of a transgenic mouse with runx2
under the control of cd2 promoter, which resulted in the
perturbation of thymocyte development and spontaneous
lymphoma.55 Augmented RUNX2 expression levels have
been noted in breast cancer cell lines; and RUNX2 may be
implicated in bone metastasis, reflecting its role in bone
biology.56 RUNX2 seems to be downstream of Wnt and
forms a network that is pertinent in prostate cancer cell
growth, rendering it a potential therapeutic target.8,14,57
Breast cancer metastasis suppressor 1 and
nucleosome remodeling and histone deacetylase
BRMS1 interacts with several proteins, such as reti-
noblastoma-binding protein-1 (RBP-1), the mammalian
SIN3-HDAC complex, and heat-shock protein 90
(Hsp90). BRMS1 complexes can suppress nuclear factor-
kappaB (NF-jB) activity through the inhibition of inhibi-
tor of NF-jB-alpha (IjBa) phosphorylation and subse-
quent degradation.58 BRMS1 contributes to direct
suppression of the transcription factor p65 (RelA)/p65
subunit of NF-jB through HDAC1-catalyzed deacetyla-
tion, whereas BRMS1 knockdown permits the recruit-
ment of acetylated RelA/p65 to NF-jB–dependent
antiapoptotic target genes.19 In addition, BRMS1 can reg-
ulate the levels of microRNAs (miRNAs) that play a role
in metastasis.8,20
The NURD complex is an ATP-dependent chroma-
tin remodeling complex that can recruit HDAC1,
HDAC2, and LSD1. It is involved in the preservation of
DNA integrity and can function either as a tumor pro-
moter or a tumor suppressor in a context-specific man-
ner.24,25 It is suggested to play a role in tumor initiation,
progression, and invasion. NURD complexes inhibit p53
through deacetylation interactions with snail zinc finger
protein (SNAIL) and twist-related protein (TWIST) dur-
ing EMT. Metastasis-associated protein 1 (MTA1), a
NURD component, can be up-regulated by the oncogene
myc (v-myc-myelocytomatosis viral oncogene homolog
[avian]), correlating with invasion and a poor outcome in
a wide spectrum of tumors.24,25 In breast cancer, human
epidermal growth factor receptor 2 (HER2) signaling up-
regulates MTA1, whereas MTA1 and MTA2 inhibit
estrogen activity. MTA3, another NURD component,
competes with MTA1, inhibits EMT, and inhibits TGF-
b and mitogen-activated protein kinase (MAPK) tumori-
genic signaling.24-26 In APL, NURD is recruited by the
fusion protein PML-RARa, impairing cell differentia-
tion.27 In addition, resveratrol (3,40,5-trihydroxystilbene;
a natural polyphenolic compound) activates p53 in pros-
tate cancer cells by MTA down-regulation and NURD
destabilization, an effect that is enhanced by HDAC inhi-
bition.28 A low-molecular-mass compound that mimics
the function of an MTA1 splice variant, which regulates
estrogen nuclear localization, has demonstrated anticancer
effects in an in vivo model.29
DISCUSSION
Outlook
The main role of transcriptional corepressors is to modify
the structure of chromatin and, thus, decelerate gene tran-
scription. In cancer, elevated levels (or enhanced function)
of corepressors may be linked to tumor suppression gene
silencing. Conversely, reduced levels (or impaired func-
tion) of corepressors can result in overexpression of
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oncogenes. In cancer, the relative ‘‘plasticity’’ that charac-
terizes the normal cell transcriptional process may be dis-
rupted and replaced by a dysfunctional ‘‘rigidity’’ that can
stimulate uncontrolled cell proliferation, lack of differen-
tiation, and inability of the cell to undergo apoptosis.
Abnormal corepressor expression, localization, structure,
and biomolecular interactions in the nuclear microenvir-
onment can translate into the deregulated activity of his-
tone-modifying enzymes, altered histone modification
(ie, methylation, acetylation), and either transcription
aberration or impairment.8
Contrary to fixed gene mutations, epigenetic modi-
fications can be reversible and potentially altered by the
administration of small-molecule drugs that can interfere
with the structure and functional interactions of transcrip-
tional coregulators, and corepressors in particular (Fig. 1).
Many strategies for therapeutic targeting of transcrip-
tional corepressors are plausible (Table 2).31 Transcrip-
tional coregulators are characterized by modular
composition and occasionally by unique presence in can-
cer cells (ie, fusion oncoproteins). Nevertheless, the phar-
macologic manipulation of both transcription factors and
transcriptional coregulators remains a difficult task. Tra-
ditional drug discovery tools, such as high-throughput
screening of compound libraries or de novo drug synthesis
by organic chemistry, have failed to generate effective cor-
epressor-targeting compounds that can be used as thera-
peutic agents. Transcription (co-)factors have convoluted
structures with large surfaces; they lack ‘‘hot spots’’ or
deep binding sites; and they are located in the nucleus
and, thus, are considered ‘‘poorer’’ drug targets. The phar-
maceutical industry has indicated little interest in inves-
ting in the development of small-molecule drugs against
these complicated macromolecules and, instead, has
attempted to target upstream ligands, receptors, or kinases
that participate in signal transduction. However, this
approach lacks specificity and has limited potential, con-
sidering the redundancy as well as the highly dynamic,
continuous cross-talk among signaling cascades (Fig. 2).
Targeting distinct domains/motifs as well as DNA-pro-
tein/protein-protein interactions of transcription factors
and coregulators (corepressors, in this case) through small
molecules can exert more selective effects at the exact site
of gene transcription, where the final ‘‘transcription deci-
sions’’ are made by integrating incoming signals (Fig. 2).
Rapid advances in biotechnology, systems biology,
translational bioinformatics, and computational chemis-
try hold the promise of discovering and/or synthesizing
sophisticated, targeted agents that can alter the activity of
transcriptional corepressors. Structure-based design
Figure 1. Various extracellular cues can instigate signals that are transduced through the cytoplasm and enter the nucleus to reg-
ulate the activity and fine-tune protein-protein interactions of transcriptional regulators in a context-specific and time-specific
manner (spatiotemporal control). Targeting selective aspects of corepressor biochemistry can alter chromatin structure/func-
tional dynamics and, thus, influence transcriptional activity of cancer-related target genes. ECM indicates extracellular matrix; TF,
transcription factor.
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techniques, such as nuclear magnetic resonance (NMR)
spectroscopy, protein-ligand x-ray crystallography, and
molecular modeling with robust computational mathe-
matical platforms of ligand docking and conformational
analysis, can support the generation of refined com-
pounds that target specific interactions of transcriptional
corepressors. The candidate molecules should be further
assessed in validated in vitro and in vivo cancer models
before they enter clinical investigation in humans.
Novel HDAC inhibitors already have demonstrated
clinical benefit and have been officially incorporated into
the anticancer armamentarium. Other promising alterna-
tives include artificial transcription (co-)factor mimics,
consisting of normal factors conjugated with synthetic
compounds targeting DNA-protein or protein-protein
interactions. RNA interference (RNAi) approaches and
antisense or decoy oligonucleotides also can be used to
manipulate transcriptional events. In that regard, the de-
velopment of novel drug-delivery systems is becoming in-
evitable, including cell-penetrating peptides (natural or
synthetic membrane-crossing molecules), viral delivery
vectors (generated from engineered viruses), and nonviral
formulations (liposomes, [lipo]polyplexes, nanoparticles).
The notion of synthetic lethality offers an additional
mechanism for transcriptional corepressor targeting. It is
believed that 2 genes (or proteins) are synthetically lethal
when concurrent impairment in both results in cell death,
whereas either alone can sustain survival. Thus, targeting a
gene/protein that is synthetically lethal to a tumor-
engaged, abnormal corepressor could selectively harm tu-
mor cells and spare normal cells.59 Such approaches can
increase the therapeutic window and, thus, provide high
efficacy with less toxic adverse effects.
There are several examples of transcriptional core-
pressor targeting. In the clinical arena, vorinostat, a pan-
HDAC inhibitor, and romidepsin, a bicyclic pan-HDAC
inhibitor, have been approved by the US Food and Drug
Administration for the management of relapsed or refrac-
tory, cutaneous T-cell lymphoma.60 Currently, there are
210 clinical trials evaluating the role of vorinostat and 50
trials of romidepsin in various hematologic and solid
organ malignancies (available at: http://clinicaltrials.gov;
accessed October 1, 2012).
In the preclinical setting, it has been demonstrated
that NCoR1 expression and activity distort the peroxi-
some proliferator-activated receptor (PPAR)a/c gene
targets that regulate cell-cycle proteins, such as cyclin-de-
pendent kinase inhibitor 1A (CDKN1A) and TGF-b re-
ceptor-associated protein-1 (TRAP1; also TGFBRAP1).
Both HDAC inhibition and ncor1 knockdown augment
antiproliferative sensitivity to PPARa/c ligands in pros-
tate cancer cell lines.61 In addition, HDAC inhibitors
exert antiproliferative and proapoptotic effects on prostate
cancer cells, and the implication of HDAC in silencing
androgen receptor (AR) signaling has therapeutic poten-
tial.62 These effects appear to be specific for prostate can-
cer AR-positive cells and correspond to formation of the
AR-SMRT complex. Although HDAC inhibitors can be
potent anticancer agents, they act against several HDAC
family members, potentially resulting in various toxic-
ities.63 Therefore, it is critical to specify the cancer-related
TABLE 2. Potential Mechanisms of Corepressor
Targeting in Cancer





Direct inhibition of enzymatic or binding domain
‘‘Allosteric’’ inhibition of enzymatic or binding domain
Artificial corepressors with high specificity (mimics)
Corepressor-related pathways/synthetic lethality
Abbreviations: RNAi, RNA interference.
Figure 2. This schematic representation of 2 intracellular sig-
naling pathways illustrates redundancy (ie, kinase B [KB] and
KD are used by both) and extensive cross-talk (dotted
arrows; a kinase in 1 pathway may use a downstream kinase
in the other pathway as substrate). The frequently deregu-
lated in cancer mitogen-activated protein kinase pathway,
with its various isoforms, can be viewed as a representative
example. Conventional therapeutics target extracellular
ligands (L1 and L2; eg growth factors), transmembrane recep-
tors (R1 and R2; eg receptor tyrosine kinases), or kinases
(KA-KE, KA0-KE0) that participate in signal transduction rather
than transcription factors (TF) (common effector of KE and
KE0 activation), coactivators (CoA), or corepressors (CoR).
KA through KE and KA0 through KE0 are hierarchical kinase
cascades (vertical arrows) in the 2 pathways. The asterisk on
KC indicates a putative mutation that may have an impact on
its catalytic activity.
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HDACs in a tumor type and to design selective inhibitors
that target specific biochemical interactions.
Considering the expression and role of NCoR in
maintaining an undifferentiated neural stem cell state
through transcriptional repression, agents that promote
NCoR phosphorylation and subsequent translocation to
the cytoplasm can result in astroglial differentiation.64
The treatment of glioma cells with a combination of
retinoic acid and low-dose okadaic acid reduced the core-
pressor effect of NCoR and exerted a significant synergis-
tic effect on growth inhibition, providing the rational
for differentiation-based therapeutic strategies in brain
tumors.64 Moreover, a competitive small molecule effec-
tively disrupted NCoR complex function/expression,
leading to NCoR cytoplasmic translocation and subse-
quent tumor cell differentiation and/or death. Therefore,
targeting of NCoR function in the cancer stem cell com-
ponent of gliomas may be beneficial and should be further
evaluated.65 In addition, miRNA-10a/b can affect neural
cell differentiation through direct targeting of NCoR2,
inducing a major reprogramming of transcriptome,
including N-myc down-regulation.66What is more, genis-
tein, a potent modifier of NCoR protein conformation,
induced apoptosis and cell-cycle arrest and promoted cell
differentiation in both retinoic acid-sensitive and retinoic
acid-resistant APL cells.67 Genistein up-regulated PML
and NCoR expression, resulted in PML-RAR degrada-
tion, and reorganized the microspeckled distribution of
PML oncogenic domains, underlining the potential value
of protein conformation-based therapies in APL. In breast
cancer cells, targeting of the adaptor protein Tab2
(TGFb-activated kinase 1-binding protein 2), which
interacts with ERa/NCoR, has been suggested as a novel
approach to revert tamoxifen resistance.68 Another treat-
ment paradigm is to block NCoR2 binding by oncogenic
fusion proteins (RUNX1-ETO) and, thus, disrupt the
repressor protein complex, restoring cell differentiation in
leukemia cells.69
The CTBP dehydrogenase substrate MTOB can act
as a CTBP inhibitor at high concentrations, causing cyto-
toxicity and apoptosis through a p53-independent mecha-
nism, as mentioned above.10 These effects correlate with
the derepression of the proapoptotic CTBP repression tar-
get Bik (Bcl-2–interacting killer), suggesting that CTBP
inhibition may provide a suitable anticancer strategy. In
human colon cancer cell peritoneal xenografts, MTOB
therapy decreased tumor burden and induced apoptosis.
In addition, the potential role of CTBP targeting to
reverse breast cancer chemoresistance merits further
investigation.70
Another example of epigenetic targeting in cancer
includes the use of hypomethylating agents (azacitidine,
decitabine) in myelodysplastic syndrome and acute mye-
loid leukemia.71 Currently, there are 223 clinical trials
investigating the role of azacitidine and 127 trials of deci-
tabine in several cancers (available at: http://clinicaltrials.-
gov; accessed October 1, 2012). However, there is a need
to understand the biologic mechanisms that underlie
treatment response to these compounds and a need to
identify specific epigenetic targets. It is interesting to note
that BRMS1 recently was identified as a novel target of
epigenetic silencing because of promoter hypermethyl-
ation, which supposedly may be susceptible to therapeutic
manipulations.21
Another way to view the potential clinical useful-
ness of transcriptional corepressors is their use as prog-
nostic and/or predictive biomarkers. A prognostic
biomarker is a surrogate of outcome, such as cancer stage
and grade. A predictive biomarker is a surrogate that can
yield information about the probability of benefit or tox-
icity from a specific therapeutic intervention. Examples
include the expression of ER concerning response to
antiestrogen therapy or HER2 expression regarding
response to trastuzumab (anti-HER2 humanized mono-
clonal antibody) in metastatic breast and gastric cancer.
A candidate biomarker can be identified, for instance,
through genome-wide association studies that can iden-
tify a gene signature, which can distinguish normal tissue
from cancer tissue. However, before a corepressor can be
considered a suitable biomarker toward better tailored
treatment among the available drugs, it needs to display
vigorous analytic validity, biologic relevance, and clinical
significance through appropriate and rigid testing
methods.
To conclude, transcriptional corepressors are con-
sidered vital for the regulation of gene transcription, and
they often are deregulated in malignant cells, promoting
transcriptional ‘‘inflexibility.’’ Elucidating the spatiotem-
poral circuit of DNA/chromatin-transcription factors-
coregulators, noncoding RNAs (including miRNAs),
epigenetic alterations, and their interactions, in the can-
cerous state (transcriptome/epigenome mapping of tu-
mor cells from individual patient samples), can open
new routes for the development of low-molecular-mass
compounds that may re-establish transcriptional ‘‘plas-
ticity’’ and, thus, bridle the anomalous cancer cell behav-
ior. Nonetheless, drug discovery and design tools should
undergo major refinement before successful corepressor-
targeted approaches demonstrate actual benefits in the
clinical setting.
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